[Edaily Reporter NA EUN-KYUNG ] Coreline Soft Co., Ltd.(384470)announced on the 29th that it will participate in the Lung Cancer Screening and Thoracic Platform Symposium to be held on July 4 at the Sheraton Grand Taipei Hotel in Taipei, Taiwan, where it plans to share its clinical and operational experience with local medical professionals regarding lung cancer screening CT (LCS).

This symposium is significant as it takes place at a time when Taiwan’s lung cancer screening market is moving beyond the initial implementation phase and entering a stage of operational refinement. Since 2022, when Taiwan incorporated low-dose computed tomography (LDCT)-based lung cancer screening into its national cancer screening system, the country has been operating a government-supported lung cancer screening program focused primarily on individuals with a family history of the disease and heavy smokers. Since last year, the eligibility criteria for screening have been expanded, and with the emergence of additional subsidy models at the local government level this year, observers note that lung cancer screening has entered a phase where it is transforming not only early diagnosis policies but also hospital operational systems and the use of medical artificial intelligence (AI).

The Taiwanese model is drawing attention due to its risk group structure, which differs from that of Western lung cancer screening programs. Lung cancer screening in the United States and Europe has primarily been designed for long-term smokers. In contrast, Taiwan has included non-smokers with a family history of lung cancer and high-risk women in its national screening program. This structure reflects the epidemiological characteristics of East Asia, including Taiwan, where the proportion of lung cancer cases among non-smokers—particularly among non-smoking women—is high.

This approach became even clearer with the expansion of the program in 2025. Taiwan’s health authorities lowered the screening age for individuals with a family history of lung cancer to 45–74 for Namsung and 40–74 for women, and relaxed the criteria for heavy smokers, adjusting the threshold to 20 pack-years or more (the cumulative smoking volume equivalent to smoking one pack a day for 20 years). As the threshold for screening has been lowered, the eligible population has expanded, and hospitals are facing the growing challenge of handling the increase in the actual volume of tests and image interpretations.

A notable trend this year is the movement toward further expansion at the local government level. Taoyuan City is implementing an “Expanded Lung Cancer Screening Program” this year, providing financial assistance for LDCT scans to residents aged 40 and older who have risk factors such as smoking exposure, related diseases, family history, occupational exposure, air pollution, and cooking fumes. This is an attempt to supplement the central government’s criteria—which focus on family history and heavy smokers—by including environmental, occupational, and lifestyle factors in the definition of high-risk groups.

Of course, this move does not immediately imply a change in national screening criteria across Taiwan. While LDCT screening is highly effective for early diagnosis, there are challenges that need to be addressed, such as managing false positives, the potential for overdiagnosis, the burden of follow-up tests, and variations in image interpretation quality across medical institutions. Consequently, Taiwan’s lung cancer screening policy is likely to evolve not simply by expanding the target population, but by gradually refining the criteria for high-risk groups and the hospital operational systems while accumulating actual screening data.

In line with these changes, the role of medical AI is also evolving. In the early stages of the lung cancer screening market, AI’s core function was the detection of pulmonary nodules. However, as the volume of screenings increases and the number of patients requiring long-term follow-up grows, hospitals require more than just simple detection capabilities. The importance of solutions that support tracking changes in nodule size and characteristics, standardized reporting, management of false positives, scheduling of follow-up examinations, multi-center quality control, and streamlining the interpretation process is growing.

At this symposium, Coreline Soft Co., Ltd. plans to introduce its experience in operating AI for lung cancer screening and case studies of multi-disease analysis based on chest CT—including interstitial lung disease (ILD)—as part of its strategy to expand lung cancer screening CT into a diagnostic platform covering a wide range of thoracic diseases in response to these market changes. Through this, the company plans to strengthen collaboration with key opinion leaders (KoLs) in Taiwan and engage in detailed discussions regarding the lung cancer screening interpretation process and the demand for AI-based multi-disease analysis.

Coreline Soft Co., Ltd. currently supplies its solutions to more than 60 medical institutions out of approximately 200 hospitals in Taiwan that are capable of adopting AI. In particular, the company has established a strong track record of success primarily with leading medical institutions, including NTUH, Chang Gung Memorial Hospital, Taipei Medical University, and Kaohsiung Medical University.

The recent upgrade of Coreline Soft Co., Ltd.’s lung cancer malignancy prediction and diagnostic assistance software, “eView LCS+ 2.0,” can also be interpreted in this context. A Coreline Soft Co., Ltd. official explained, “The fact that hospitals using our existing solutions chose to pay for an upgrade to the latest version rather than switching to competing products demonstrates that the solution has become firmly established within their internal operational structures, going beyond simple maintenance.”

Coreline Soft Co., Ltd. anticipates that as lung cancer screening expands through government policies, the volume of CT scans and interpretations at individual hospitals, as well as post-screening follow-up data, will increase accordingly. The company explains that if AI is repeatedly used within actual clinical practice during this process, the revenue model can expand beyond initial installation sales to include usage-based billing (PPU), subscription services, feature upgrades, and long-term maintenance—creating a recurring revenue structure.

Coreline Soft Co., Ltd. is also continuing to expand its portfolio of chest CT-based multi-disease analysis solutions, similar to its emergency AI product line for conditions such as cerebral hemorrhage, aortic dissection, and pulmonary embolism.

A representative of Coreline Soft Co., Ltd. stated, “While early detection of lung cancer remains the focus of Taiwan’s national screening program, demand for utilizing additional information detectable via chest CT—such as emphysema, coronary artery calcification, and interstitial lung abnormalities—is expected to grow as more screening CT data is accumulated.”